Engflag

Platsul A

Quick links to important sections

Platsul A

Platsul A_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Platsul A

Quick Facts

Property Description
Active Ingredients Silver Sulfadiazine, Lidocaine, Vitamin A, Vitamin D
Form Cream, Dermal Ointment (Ungüento)
Pharmacological Class Topical Antibacterial, Local Anesthetic, Epithelializing Agent
Route of Administration Topical Dermal (Cutaneous)
Type Multi-component Combination Drug

Platsul A is a distinct multi-component pharmaceutical preparation formulated exclusively for topical dermal administration, positioning it as a combination drug that simultaneously integrates infection control, pain relief, and skin support. It is generally supplied as an emollient cream or a thick dermal ointment (ungüento). The preparation is used in medical practice for the management of superficial skin damage.

What Type of Medicine is Platsul A?

Platsul A is characterized as a topical antibacterial and local anesthetic agent, moving beyond the functional scope of single-action dermatological treatments. The primary sulfonamide antibacterial component, Silver Sulfadiazine, is a broad-spectrum agent used for managing surface microbes and preventing contamination. The formulation's design reflects a strategic approach to managing complex superficial skin injuries.

The Composition and Core Ingredients

The formulation features four distinct active ingredients: Silver Sulfadiazine, Lidocaine (often as Lidocaine Hydrochloride), Vitamin A (Retinol), and Vitamin D (Calciferol). Silver Sulfadiazine provides the synthetic broad-spectrum bactericidal antimicrobial action. The inclusion of Lidocaine, an amide-class local anesthetic, functions by blocking nerve signals at the application site. The Vitamins A and D are natural derivatives that assist the physiological processes of tissue maintenance and regeneration. These agents are compounded into an emollient cream base suitable for application to compromised skin.

Platsul A's General Therapeutic Purpose

The preparation’s general therapeutic purpose is to provide comfort and foster a supportive environment for skin repair. The combination is designed to simultaneously control surface bacteria and mitigate acute discomfort through local anesthesia. By integrating these effects with agents that support re-epithelialization, Platsul A serves as a comprehensive preparation that assists the body's natural wound healing mechanisms.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Platsul A?

Possible Side Effects and Safety Information

The safety profile of this multi-component topical preparation is defined by the officially documented adverse reactions associated with its primary active ingredients, particularly the sulfonamide component, Silver Sulfadiazine. The regulatory safety framework classifies potential effects by frequency and the body system affected, based on data documented by government health authorities.

Common and Expected Adverse Reactions

Adverse reactions classified as common in official labeling are typically localized to the application site. These include a burning sensation, local pain, pruritus (itching), and skin rash. These effects are generally transient and are categorized within Skin and subcutaneous tissue disorders.

Systemic and Serious Reactions

When applied to extensive areas, the sulfonamide component may be absorbed systemically, leading to the potential for less common, but more serious, adverse reactions classified in other System-Organ Classes.

System-Organ Class Key Adverse Reaction (Label-Documented)
Blood and lymphatic system disorders Leukopenia (decreased white blood cell count), often transiently observed within the first few days of treatment.
Immune system disorders Potential for Hypersensitivity reactions and cross-sensitivity with other sulfonamide drugs.
Serious Adverse Reactions Officially documented severe, rare risks include Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and blood disorders such as Agranulocytosis.

Population-Specific Safety Considerations

The regulatory profile specifies constraints for vulnerable groups. The preparation is contraindicated in premature infants and neonates under two months of age due to the risk of Kernicterus. Use is also restricted in pregnant women approaching term and requires caution in individuals with G6PD deficiency due to the increased risk of Haemolysis, as stated in official prescribing information. The risk of systemic adverse reactions is greater with application to large body surface areas or during prolonged use.

Overdose and Emergency Response

Overdose from this topical preparation is primarily a concern when extensive systemic absorption occurs, such as when the cream is applied to large, compromised areas of skin like severe burns. The official regulatory profile is defined by the potential systemic toxicity of its active ingredients, Lidocaine and Silver Sulfadiazine.

Excessive Lidocaine absorption may lead to severe Central Nervous System (CNS) and Cardiovascular manifestations. Documented presentations include nervousness, dizziness, blurred vision, and tremors. In severe cases, systemic toxicity can lead to convulsions, marked hypotension, and cardiac arrest.

Systemic absorption of Silver Sulfadiazine carries the risk of sulfonamide-related adverse effects, which involve hematological abnormalities. These include blood dyscrasias, such as leukopenia and agranulocytosis, as well as potential renal damage (crystalluria) and hepatic necrosis. Specific population risks exist for patients with impaired renal or hepatic function, who may experience increased drug accumulation. Use is not recommended for newborn infants due to the potential risk of kernicterus.

Official guidelines mandate that the product be discontinued immediately upon any sign of systemic toxicity. Immediate medical attention or contact with emergency services must be sought for the appearance of serious symptoms like tremors, difficulty breathing, or changes in heart rate. Management involves symptomatic and supportive treatment, including monitoring renal function and blood counts.

Therapeutic Uses of Platsul A

The primary therapeutic area for this combination cream is wound care following severe skin injury. The preparation is commonly used to prevent and treat infection in second- and third-degree burns, conditions characterized by heightened physiological stress.

Management of Infection Risk in Serious Manifestations

The preparation is applied in clinical settings that involve acute or unstable symptom patterns, such as burns. It is relevant for managing the heightened risk of wound sepsis in situations where the skin is compromised. This protective function may assist with maintaining functional stability by managing symptoms related to inflammatory or irritative states. This support contributes to easing the overall symptom load and supports the patient during the high-risk, acute recovery phase.

Relief of Acute, Localized Discomfort

The preparation is applied to provide symptomatic relief for acute, localized pain and physical discomfort. This benefit is applied across domains where short-term symptom management is appropriate. This supportive relief helps to improve day-to-day comfort and assists with maintaining functional stability when symptoms are more noticeable.

Supportive Healing in Chronic Symptom Domains

This agent is used to support the patient during difficult episodes by easing distress and supporting overall well-being. It is commonly used across conditions presenting with chronic or recurrent symptomatic manifestations, such as ulcers, where short-term symptomatic assistance is needed.

Quick Fact: Primary Therapeutic Context
Symptom Axes: Symptoms related to physical discomfort and inflammatory or irritative states.
Clinical Context: Applied in clinical settings that involve acute or unstable symptom patterns, such as burns.
Benefit: Contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress.

Regulatory References

  1. Silver Sulfadiazine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Must Not Use Platsul A (Contraindications)

Official regulatory documents state that Platsul A is contraindicated and must not be used by specific populations. These include individuals with a known hypersensitivity or allergy to Silver Sulfadiazine or other sulfonamide medicines. Use is also strictly prohibited in premature infants and newborns during the first 2 months of life (less than le 2 months old), as well as in pregnant women approaching or at term. These restrictions are in place due to the documented risk of kernicterus from sulfonamide absorption. Furthermore, use is generally not recommended for nursing mothers.

Conditional Eligibility and Restrictions

Use of Platsul A requires caution and monitoring in patients with certain pre-existing conditions. These restrictions apply to individuals with impaired hepatic function (liver disease) or impaired renal function (kidney disease). Caution is also advised for patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. The product is approved for use in adults and children 2 months of age and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interactions for the active components of Platsul A (Silver Sulfadiazine and Lidocaine), based strictly on regulatory prescribing information.

Co-administration with Methenamine is formally contraindicated due to a documented risk of crystalluria formation related to the sulfonamide component.

Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Official Interaction Outcome
Oral Hypoglycemic Agents & Phenytoin Effects can be potentiated where serum sulfadiazine levels approach therapeutic concentrations, requiring blood concentration monitoring.
Topical Proteolytic Enzymes The silver component may inactivate these enzymatic agents, making their concomitant use inappropriate.
Cimetidine Concurrent use with Silver Sulfadiazine is associated with an increased incidence of leukopenia.
Class I Antiarrhythmic Drugs (e.g., Tocainide) Toxic systemic effects are additive and potentially synergistic with absorbed Lidocaine.
Other Local Anesthetic Agents Total absorbed exposure must be considered to prevent additive systemic toxic effects from the Lidocaine component.

Population-Specific Interaction Notes

Regulatory documents specify that patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of Lidocaine due to altered metabolism. Similarly, if hepatic and renal functions become impaired, there is a risk of Silver Sulfadiazine accumulation.

Mechanism of Action

Dual Mechanism of Action: Antimicrobial and Regenerative

The drug's activity is based on a synergistic dual mechanism combining antimicrobial action and host cell modulation. One component, Silver Sulfadiazine (SSD), primarily acts by inhibiting microbial growth, while the other, Retinol (Vitamin A), directly modulates host cell functions to stimulate tissue rebuilding. This combined approach results in the complementary effects of antimicrobial activity and host cellular proliferation.

Inhibition of Microbial Growth Pathways

SSD exerts its effect by targeting microbial physiology in two ways: the silver ion component disrupts the microbial cell membrane and essential enzymes, and the sulfadiazine component functions as a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase, blocking folic acid synthesis. This disruption of fundamental microbial metabolic and replication pathways leads to a reduction in the concentration of viable microorganisms at the site of application.

Transcriptional Activation of Cellular Renewal

The Retinol component is metabolized into Retinoic Acid, which engages Nuclear Retinoid Receptors (RARs and RXRs) within host cells. This interaction modulates gene transcription, specifically upregulating processes for cell division and differentiation (re-epithelialization) and the synthesis of structural proteins like collagen in the dermal layer. This activity enhances the rate of cellular turnover and the deposition of structural matrix proteins.

Dosage and Administration Information

How to Use Platsul A: Administration Guidelines

Platsul A is a topical medication, with Silver Sulfadiazine as its primary component. The following instructions define the standard method for use and administration.

Administration Scope Instruction
Route of Administration Topical (Dermal/Cutaneous application). For external use only.
Dosing Schedule & Thickness Apply a continuous thin layer, approximately 1.5 mm to 2.0 mm thick, sufficient to cover the entire wound surface.
Preparation Requirements The wound must be washed (cleansed) with sterile water and thoroughly dried before the application of the cream.
Frequency & Timing Application is typically once or twice daily (qDay to q12hr). The cream must be reapplied immediately if it is rubbed or washed off to maintain continuous coverage.
Application Method Apply with a sterile gloved hand or sterile spatula to minimize contamination. Avoid all contact with the eyes.
Duration of Use Continue application until complete re-epithelization of the wound or until the wound is ready for skin grafting.

Restrictions on Use

Administration is strictly prohibited in premature infants and newborns/infants less than 2 months of age due to systemic absorption risks.

Procedural Summary

The correct use protocol requires that the area is first cleansed and dried, followed by the application of the cream at the specified layer thickness. The instructions establish a standardized regimen of continuous coverage, reinforcing that this is a topical treatment with strict limitations on use in the infant population.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Platsul A is a topical formulation containing silver sulfadiazine and lidocaine (lignocaine), which is primarily studied for its role in wound management and burn care. The clinical research focuses on the antibacterial properties of silver sulfadiazine combined with the local anesthetic effects of lidocaine.

Efficacy and Wound Healing

Studies have evaluated the combination of silver sulfadiazine and lidocaine in the context of wound and burn healing.

  • Silver Sulfadiazine (SSD): SSD is a widely used topical antimicrobial agent intended to prevent bacterial colonization in burn wounds. Research has investigated its role in controlling microbial load, which is critical for reducing the risk of wound infection. However, some preclinical and clinical studies have explored whether SSD's effect on cellular processes, such as re-epithelialization and wound contraction, might be delayed compared to certain alternative dressings.
  • Lidocaine: As a local anesthetic, lidocaine is included to provide local pain relief by reversibly blocking nerve impulse propagation. Clinical data supports the use of topical lidocaine formulations for pain management in various skin conditions and procedures, a benefit utilized in the overall patient experience with Platsul A.

Specialty Applications

Limited prospective case series have investigated Platsul A's aerosol formulation in treating complex wounds, such as scalp pressure ulcers (SPUs) in patients admitted to intensive care units (ICUs). These preliminary studies aimed to assess its potential for facilitating healing and managing wound progression in this specific patient population. Further and larger studies are warranted to confirm these initial observations and determine clinical applicability across broader wound types.

Frequently Asked Questions (FAQ)

Common questions about Platsul A (FAQ)

Q: What is the primary action of Platsul A?

Platsul A is officially classified as a topical anti-infective. Its main regulatory role is to help prevent or manage bacterial infections in skin wounds, such as those resulting from burns, skin grafts, or ulcers. Regulatory documents state that its active ingredient works to control the growth of bacteria that can potentially complicate wound healing.

Q: Does Platsul A help with pain relief in a burn injury?

According to the official product information, the primary function of Platsul A is its anti-infective action against bacteria. The medication is not primarily classified as a pain reliever (analgesic). Any comfort provided is secondary to its main regulatory purpose of infection management.

Q: What should I do if I miss an application of Platsul A?

Official product information generally suggests that if an application is missed, it should be applied when remembered, and then the patient should follow the regular prescribed schedule. However, for specific instructions on managing missed doses, patients should always refer to the detailed package insert or consult their prescribing healthcare professional.

Q: Can I use Platsul A on children under the age of two?

Regulatory documents state that Platsul A should not be used in premature infants or in full-term infants during the first two months of life. This exclusion is based on safety concerns documented in official product information for this very young age group. Decisions about use in older children must be made by a qualified healthcare professional.

Q: Is it normal for the treated area to change color while using Platsul A?

Studies and official product information note that a change in the color of the skin, nails, or wound may occur with the use of Platsul A. This effect is related to the presence of Silver in the formulation and is often temporary. Patients should always discuss any observed changes or side effects with a healthcare professional.

How should Platsul A be stored and disposed of?

Storage and Handling Requirements

Platsul A cream must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), to maintain product stability. It is mandatory that the medicine be kept in its original container, tightly closed, and stored away from excess heat and moisture. The cream must not be frozen.

Child Safety and Disposal

The product must be stored out of the sight and reach of children to prevent unintentional exposure. For disposal, unused or expired Platsul A should not be kept. Patients should consult a healthcare professional or utilize an official drug take-back program for proper disposal. If household trash disposal is necessary, the medication must be mixed with an undesirable substance, placed in a sealed container, and then discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Platsul A found in:

A-Z Index: